THERADIAG news, videos and press releases
For more news please use our advanced search feature.
THERADIAG - More news...
THERADIAG - More news...
- Theradiag Reports Revenue of €6.7 Million for the First Half of 2023, up 6.8%
- Theradiag Announces Its 2022 Full-Year Results and 2023 First Quarter Revenue
- Theradiag: New 2023 Financial Agenda
- Theradiag: Change of Governance
- THERADIAG Reports 2022 Revenue of €12.2 Million, up 9.7%
- THERADIAG Announces Its 2023 Financial Calendar
- Theradiag: Downward Adjustment of the Sales and Profitability Targets For 2026
- Theradiag: Appointment of an Independent Expert
- Theradiag Announces That Biosynex Has Filed a Voluntary Takeover Bid for Its Shares
- Theradiag Announces Its Results for the First Half of 2022: Breaking-Even and Confirming Its Ability to Be Structurally Profitable From Early 2023
- Theradiag Reports Revenue of €6.3 Million for the First Half of 2022, Up 14.3%
- Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics
- THERADIAG Announces the Launch of ez-Track1, a Point-of-Care Testing Solution for Therapeutic Drug Monitoring
- Theradiag Announces the Launch of Two New i-Tracker® Kits
- Theradiag: Report of the Ordinary and Extraordinary General Meeting of 5 May 2022
- Theradiag: Change in the Composition of the Board of Directors to Be Voted on at the Annual General Meeting of May 5, 2022
- Theradiag Announces Its 2021 Full-Year Results
- THERADIAG Posts 2021 Revenue of €11.1 Million, up 7%
- Theradiag: Signing of a Distribution Agreement with BIOSYNEX of Their AMPLIQUICK SARS-CoV-2 PCR Test
- THERADIAG Announces Its 2022 Financial Calendar
- THERADIAG Announces the Launch of 4 New i-Tracker® Kits and the Validation of a New Parameter in the United States
- THERADIAG notes the acquisition of a stake in its capital by BIOSYNEX
- Theradiag Announces Its Results for the First Half of 2021
- Theradiag Reports Revenue of €5.5 Million for the First Half of 2021, Up 12.5%
- Theradiag: Report of the Extraordinary General Meeting on Second Call of June 10, 2021
- Theradiag Announces the Launch of HUMABDIAG, a Large-scale Research Project Targeting the Bioproduction of Monoclonal Antibodies in Tours
- Theradiag Announces the Adoption of All Ordinary Resolutions at the Shareholders’ Meeting of May 6, 2021
- Theradiag Announces Its 2020 Full-year Results
- Theradiag Posts 2020 Revenue of €10.4 Million, up 8.0%
- THERADIAG Signs a Contract to Supply ORGENTEC With Quality Control Reagents Called Alegria® Check
